{"product_id":"yi-five-forces","title":"(YI) 111, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 111, Inc. Porter's Five Forces Analysis helps you assess the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the actual report content, so you can review it before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand-Name Drug Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrand-name drug makers have strong supplier power because patented and high-quality drugs can command better pricing and distribution terms. 111, Inc. relies on these brands to keep its prescription and premium mix attractive, so it has limited room to switch. When supply tightens or demand turns seasonal, input costs can rise fast and squeeze margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Approval Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers with approvals, certifications, or controlled distribution rights have more leverage because 111, Inc. cannot switch fast on regulated healthcare items. Compliance rules and product registration slow substitution, so even small supplier groups can protect pricing. That weakens 111, Inc.'s bargaining power on items tied to permits, licenses, or exclusive channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFragmented Commodity Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor generics, wellness goods, and medical consumables, 111, Inc. faces a fragmented supplier base, with many manufacturers and distributors competing for shelf and platform access. That structure keeps supplier power in check because buyers can switch across comparable products fast, and commoditized items rarely support pricing control. In its 2025 filings, the company still relied on a broad, multi-source catalog rather than a few dominant vendors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCold Chain and Logistics Dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e111, Inc. depends on suppliers that can keep drugs and healthcare goods in stable cold-chain storage and fast last-mile delivery. These vendors matter more because temperature excursions can spoil products and halt sales, so reliable warehousing and transport raise supplier power. When logistics break down, 111, Inc. has fewer backup options and suppliers can push harder on price and terms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain control lifts supplier value.\u003c\/li\u003e\n\u003cli\u003eDisruptions weaken 111, Inc.'s leverage.\u003c\/li\u003e\n\u003cli\u003eStable fulfillment can command better terms.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSwitching and Replenishment Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e111, Inc. faces moderate supplier power because it must keep pharmacies, consumers, and partners supplied without breaks. If a key vendor misses a shipment, some SKUs can be costly or slow to replace, so replenishment risk raises supplier leverage. In healthcare retail, service gaps quickly hit trust and repeat orders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKey SKUs are hard to swap fast\u003c\/li\u003e\n\u003cli\u003eService levels depend on steady fills\u003c\/li\u003e\n\u003cli\u003eShortages raise substitution costs\u003c\/li\u003e\n\u003cli\u003eSupplier leverage stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e111, Inc. Supplier Power: Moderate, with Cold-Chain Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e111, Inc. faces moderate supplier power. Brand-name and regulated healthcare vendors can hold pricing, but generics and consumables come from a broad, multi-source base. Cold-chain and last-mile partners still matter because service breaks can stop sales fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003ePower\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatented drugs\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics and consumables\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain logistics\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall supplier power\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes 111, Inc.’s competitive pressures, supplier and buyer power, entry threats, and substitutes shaping its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick 111, Inc. Five Forces snapshot that cuts through complexity and highlights strategic pressure fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003e111, Inc. Reference Sources provide a credible audit trail that supports faster, more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice-Sensitive Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChinese online health shoppers often compare prices across platforms before buying, and that behavior gives them real leverage. Prescription and OTC products face heavy discounting pressure, so even small price gaps can shift demand fast. For 111, Inc., that means customer bargaining power stays high, especially in commoditized categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy and Wholesaler Buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e111, Inc.’s buyers are mainly B2B pharmacies and wholesalers, not end consumers, so they can place large orders and push for lower prices, rebates, and tighter service terms. China still has roughly 700,000 retail pharmacies, and buyers can shift between online and offline sources, which keeps supplier switching costs low. That scale makes pharmacy and wholesaler buyers the stronger side in negotiations, especially when service speed and fill rates slip.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEasy Channel Switching\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEasy Channel Switching keeps buyer power high because customers can move between 111, Inc., other online platforms, and local pharmacies with little effort. App ordering and fast delivery cut loyalty barriers, so price and service become the main switch points. In China, online drug sales and pharmacy apps keep expanding, which makes 111, Inc. harder to price above rivals and limits margin power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh Service Expectations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh service expectations give customers strong leverage over 111, Inc. They want fast fulfillment, correct prescriptions, and reliable after-sales support, and even small slips can push them to other platforms. In 111, Inc.'s 2025 results, service-linked spending stayed under pressure, so customer experience remains a direct cost and retention issue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast service drives switching risk.\u003c\/li\u003e\n\u003cli\u003eAccuracy matters more than price.\u003c\/li\u003e\n\u003cli\u003eSupport costs rise to keep trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInsurance and Platform Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurance providers and integrated healthcare partners can steer 111, Inc. sales by setting claims, formulary, and data-sharing rules. China’s basic medical insurance covered about 1.36 billion people, so a large share of demand runs through payer-led channels. That gives customers power over price, service terms, and which products get pushed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClaims rules shape product access\u003c\/li\u003e\n\u003cli\u003eData-sharing raises switching costs\u003c\/li\u003e\n\u003cli\u003ePayer terms दब lower pricing power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Buyer Power Keeps 111, Inc. Margins Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer bargaining power at 111, Inc. stays high because pharmacies and wholesalers can switch across online and offline channels with low friction. China still has about 700,000 retail pharmacies, and buyers can press for lower prices, rebates, and faster service. Heavy discounting in OTC and prescription goods keeps margin power thin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies in China\u003c\/td\u003e\n\u003ctd\u003e~700,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer type\u003c\/td\u003e\n\u003ctd\u003eB2B pharmacies, wholesalers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003e111, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact 111, Inc. Porter’s Five Forces Analysis you’ll receive immediately after purchase—no samples, no placeholders, and no surprises. It’s the same professionally written, ready-to-use document displayed here, fully formatted for instant download. What you see in the preview is the final file you’ll get after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Digital Health Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e111, Inc. faces heavy pressure from JD Health and Alibaba Health, both at multi-tens-of-billions revenue scale and backed by strong brand reach. JD Health reported RMB 58.5 billion in 2024 revenue, while Alibaba Health reported HK$27.0 billion, showing how much larger the top rivals are. Rivalry is fierce in both B2C and B2B, so pricing, traffic, and supplier access stay under constant strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThin Margin Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e111, Inc. competes in a market where pharma e-commerce often wins on low margins and high order volume, so rivals lean on discounts, subsidies, and faster delivery. That keeps pricing pressure heavy and makes profit recovery hard even when sales rise. For 111, Inc., thin spread economics mean rivalry can quickly erode gross margin and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffline and O2O Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOffline and O2O rivalry is intensifying as pharmacy chains add app ordering, same-day delivery, and store pickup, so the gap between online and offline is shrinking fast. 111, Inc. now competes on price, but also on speed, local coverage, and service depth. In China, top chains have thousands of stores, which gives them a built-in reach advantage that can pressure margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct Breadth Arms Race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetition is intense because rivals win on wider assortments and faster delivery. 111, Inc. has to keep prescription drugs, OTC products, wellness items, and personal care goods in stock, which means constant sourcing and heavier platform spend. In a market where breadth and fill rate can decide the order, catalog depth becomes a direct cost center.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader mix drives customer retention\u003c\/li\u003e\n\u003cli\u003eFaster availability lifts conversion\u003c\/li\u003e\n\u003cli\u003eConstant sourcing raises working capital\u003c\/li\u003e\n\u003cli\u003ePlatform investment keeps assortment current\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTechnology and Fulfillment Race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is high because 111, Inc. competes on software, data, logistics, and pharmacy integration, not just price. In China’s online pharmacy market, same-day delivery and faster prescription flows can quickly shift demand, so rivals that improve recommendation engines or fulfillment win share fast.\u003c\/p\u003e\n\u003cp\u003eWith 111, Inc. still in a market where service speed and workflow quality decide repeat orders, even small gains in delivery time or prescription handling can matter. That keeps rivalry structurally high and makes tech spend a core competitive weapon.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSoftware drives order conversion.\u003c\/li\u003e\n\u003cli\u003eLogistics drives repeat demand.\u003c\/li\u003e\n\u003cli\u003ePharmacy links reduce friction.\u003c\/li\u003e\n\u003cli\u003eFaster service pulls share away.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e111, Inc. Faces Intense Rivalry From Bigger E-Commerce Health Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for 111, Inc. because JD Health posted RMB 58.5 billion 2024 revenue and Alibaba Health HK$27.0 billion, so scale gaps are wide. Price cuts, faster delivery, and richer assortments keep pressure on margins and cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRival\u003c\/th\u003e\n\u003cth\u003e2024 Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJD Health\u003c\/td\u003e\n\u003ctd\u003eRMB 58.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlibaba Health\u003c\/td\u003e\n\u003ctd\u003eHK$27.0 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffline Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOffline pharmacies are a strong substitute because they give instant pickup and face-to-face advice, which matters when people need medicine now. In China, the retail pharmacy network still spans hundreds of thousands of stores, so common drugs and personal care items are easy to buy nearby instead of waiting for delivery. That keeps pressure on 111, Inc. to compete on speed, price, and trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinic Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital and clinic channels stay a strong substitute for 111, Inc. because patients can fill prescriptions at the point of care, especially for chronic and acute therapy. In 2025, China’s large hospital system still anchors prescription access, so every direct hospital or outpatient dispensary fill cuts demand that might otherwise pass through 111, Inc. That makes the threat of substitutes high for prescription-led purchases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Manufacturer Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect manufacturer sales are a meaningful substitute for 111, Inc. because drug makers and health brands can sell through their own websites, flagship stores, or app channels and bypass intermediaries. That shift can pull traffic, pricing power, and order value away from marketplace platforms. In China, this direct-to-consumer route has grown fast as brands seek tighter control over margin and customer data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTelemedicine with Built-In Fulfillment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTelemedicine with built-in fulfillment raises substitution risk for 111, Inc. because other digital health apps can bundle consults, e-prescriptions, and delivery in one checkout flow. If a rival is faster or cheaper, users can switch with one tap, so loyalty is thin and price matters a lot. In China’s crowded online care market, that keeps pressure on take rates and repeat orders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundled care and delivery cuts switching friction.\u003c\/li\u003e\n\u003cli\u003eCheaper apps can win price-sensitive users.\u003c\/li\u003e\n\u003cli\u003eLow loyalty lifts substitution pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-Pharma Wellness Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-Pharma Wellness Alternatives pressure 111, Inc. because supplements, lifestyle products, and preventive care can meet part of the same demand as medicines. In low-acuity cases, consumers often delay buying or switch to cheaper generics, which widens the substitute set and caps pricing power.\u003c\/p\u003e\n\u003cp\u003eThis matters most in China’s mass-market health channel, where value-seeking buyers compare outcomes, convenience, and price before they buy. For 111, Inc., that means softer demand for OTC and wellness-linked products when non-drug options look good enough.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupplements can replace some drug demand\u003c\/li\u003e\n\u003cli\u003ePreventive care can delay medicine purchases\u003c\/li\u003e\n\u003cli\u003eGenerics widen price-based substitution\u003c\/li\u003e\n\u003cli\u003eLow-acuity demand is easiest to switch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Substitute Threat Weighs on 111, Inc.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for 111, Inc. because offline pharmacies, hospitals, and brand-owned channels can meet the same demand faster or cheaper. China’s retail pharmacy network still spans hundreds of thousands of stores, while hospital fills and direct-to-consumer sales keep siphoning orders away. Telemedicine bundles and wellness alternatives also cut switching costs and weaken loyalty.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003ePressure\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eOffline, hospital, direct, digital, wellness\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eSpeed, price, access\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory barriers are high for 111, Inc. because healthcare retail and prescription fulfillment need pharmacy licenses, drug compliance, and strict data governance. New entrants must meet rules on prescription review, patient privacy, and online dispensing, which adds time and cost before launch. That makes entry far harder than ordinary e-commerce, where a site and logistics network are often enough.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and Operating Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuilding warehouses, delivery networks, IT systems, and pharmacy ties takes heavy upfront cash, often tens of millions of yuan before a new player can even test unit economics. For 111, Inc., that scale hurdle lifts the cost and risk of entry.\u003c\/p\u003e\n\u003cp\u003eNew entrants also need enough order volume to spread fixed costs across millions of transactions; without that, delivery and compliance costs stay high. That makes it hard to match the scale advantage of established platforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrust and Brand Credibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrust is a real barrier in 111, Inc.'s market because buyers need proof of product authenticity and stable delivery. The WHO says 1 in 10 medical products in low- and middle-income countries is substandard or falsified, so shoppers and pharmacy clients favor known names. New entrants must spend heavily on compliance, verification, and service quality before they can match that credibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply Chain and Data Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e111, Inc.’s threat of new entrants is low because its links across manufacturers, distributors, pharmacies, and insurers are hard to copy fast. A new player without this data and workflow integration cannot match 111, Inc.’s service breadth or delivery speed, so existing ecosystem ties act as a strong barrier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeep partner integration is hard to replicate.\u003c\/li\u003e\n\u003cli\u003eMissing links cut speed and service range.\u003c\/li\u003e\n\u003cli\u003eNetwork ties block fast entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital Entry Is Still Possible\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital entry is still possible for 111, Inc. because tech-enabled startups can target one province, one product line, or one service layer instead of building a full national platform. That keeps the threat of new entrants moderate, not negligible.\u003c\/p\u003e\n\u003cp\u003eIn China’s online healthcare and pharmacy space, niche players can use lighter asset models and faster product rollout to test demand before scaling. 111, Inc. still has scale and partner ties, but focused entrants can chip away at narrow use cases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStart small: one region\u003c\/li\u003e\n\u003cli\u003eEnter one category first\u003c\/li\u003e\n\u003cli\u003eTarget one service layer\u003c\/li\u003e\n\u003cli\u003eThreat stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e111, Inc.: New Entrants Face High Bar, but Niche Rivals Can Still Emerge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for 111, Inc. is low to moderate because pharmacy licensing, drug compliance, data rules, and trusted fulfillment all raise the bar. Building the warehouse, delivery, IT, and partner network also needs heavy upfront cash, while scale is needed to spread fixed costs. Trust matters too: WHO says 1 in 10 medical products in low- and middle-income countries is substandard or falsified, so new rivals must spend more to win confidence. Still, niche digital entrants can start in one region or one service line, so the threat is not zero.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses and compliance\u003c\/td\u003e\n\u003ctd\u003eSlows launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeavy upfront capex\u003c\/td\u003e\n\u003ctd\u003eRaises entry cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScale and trust\u003c\/td\u003e\n\u003ctd\u003eFavors incumbents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche digital entry\u003c\/td\u003e\n\u003ctd\u003eKeeps threat moderate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235203031305,"sku":"yi-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/yi-five-forces.webp?v=1785736755","url":"https:\/\/dcfanalyst.com\/products\/yi-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}